IgG and IgM antibody formation to spike and nucleocapsid proteins in COVID-19 characterized by multiplex immunoblot assays
| Autor: | Ammar Bazerbashi, Denise Force, Hari Hara Potula, Ranjan Ramasamy, Iris Du Cruz, Jyotsna S Shah, Prerna Bhargava, Song Liu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Immunoblotting Biology Spike protein Antibodies Viral Sensitivity and Specificity Virus law.invention Serology lcsh:Infectious and parasitic diseases 03 medical and health sciences 0302 clinical medicine Antigen law Coronavirus Nucleocapsid Proteins Humans Serologic Tests Multiplex lcsh:RC109-216 030212 general & internal medicine Seroconversion Pandemics Antiserum Nucleocapsid protein Line immunoblot assay SARS-CoV-2 COVID-19 Phosphoproteins Virology Receptor-binding domain 030104 developmental biology Infectious Diseases Multiplex assay Immunoglobulin M Parasitology Immunoglobulin G Antibody Formation Spike Glycoprotein Coronavirus Recombinant DNA Research Article Serological diagnosis |
| Zdroj: | BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-8 (2021) BMC Infectious Diseases |
| ISSN: | 1471-2334 |
| Popis: | Background Rapid and simple serological assays for characterizing antibody responses are important in the current COVID-19 pandemic caused by SARS-CoV-2. Multiplex immunoblot (IB) assays termed COVID-19 IB assays were developed for detecting IgG and IgM antibodies to SARS-CoV-2 virus proteins in COVID-19 patients. Methods Recombinant nucleocapsid protein and the S1, S2 and receptor binding domain (RBD) of the spike protein of SARS-CoV-2 were used as target antigens in the COVID-19 IBs. Specificity of the IB assay was established with 231 sera from persons with allergy, unrelated viral infections, autoimmune conditions and suspected tick-borne diseases, and 32 goat antisera to human influenza proteins. IgG and IgM COVID-19 IBs assays were performed on 84 sera obtained at different times after a positive RT-qPCR test from 37 COVID-19 patients with mild symptoms. Results Criteria for determining overall IgG and IgM antibody positivity using the four SARS-CoV-2 proteins were developed by optimizing specificity and sensitivity in the COVID-19 IgG and IgM IB assays. The estimated sensitivities and specificities of the COVID-19 IgG and IgM IBs for IgG and IgM antibodies individually or for either IgG or IgM antibodies meet the US recommendations for laboratory serological diagnostic tests. The proportion of IgM-positive sera from the COVID-19 patients following an RT-qPCR positive test was maximal at 83% before 10 days and decreased to 0% after 100 days, while the proportions of IgG-positive sera tended to plateau between days 11 and 65 at 78–100% and fall to 44% after 100 days. Detection of either IgG or IgM antibodies was better than IgG or IgM alone for assessing seroconversion in COVID-19. Both IgG and IgM antibodies detected RBD less frequently than S1, S2 and N proteins. Conclusions The multiplex COVID-19 IB assays offer many advantages for simultaneously evaluating antibody responses to different SARS-CoV-2 proteins in COVID-19 patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|